In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a $13.00 …
Canaccord analyst John Newman was out pounding the table on Celgene Corporation (NASDAQ:CELG) Friday, reiterating a Buy rating and price target of $156, which represents a …
In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Kite Pharma Inc (NASDAQ:KITE) with a price …
In a research report issued Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $3.00 …
Canaccord’s healthcare analyst John Newman weighed in with a few insights on Agios Pharmaceuticals Inc (NASDAQ:AGIO), as the company’s AG-120 solid tumor data will be presented …
Canaccord’s healthcare analyst John Newman weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), after the company hosted an Analyst Day to highlight …
In a research report released Monday, Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) with a $6 price …
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) with a $6 …
Canaccord analyst John Newman weighed in today with a few insights on Kite Pharma Inc (NASDAQ:KITE), after the company informed investors that there was one …
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a $3.00 …
